Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-08-16
2005-08-16
Brumback, Brenda (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S094100, C424S094670, C530S350000
Reexamination Certificate
active
06930084
ABSTRACT:
The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are methods for identifying additional compounds that influence TNF receptor shedding. As the active ingredient in a pharmaceutical composition, the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathology of disease.
REFERENCES:
patent: 4761371 (1988-08-01), Bell et al.
patent: 5395760 (1995-03-01), Smith et al.
patent: 6083913 (2000-07-01), Dower et al.
patent: 0 657 536 (1995-06-01), None
patent: 418 014 (1995-12-01), None
patent: WO 95/31544 (1995-11-01), None
patent: WO 95/33051 (1995-12-01), None
patent: WO 96/01642 (1996-01-01), None
patent: WO 98/20140 (1998-05-01), None
patent: WO 99/58559 (1999-11-01), None
Gabay C. Cytokine inhibitors in the treatment of rheumatoid arthritis. Expert Opin Biol Ther. Feb. 2002;2(2):135-49.
Voet et al. Biochemistry. 1990. John Wiley & Sons, Inc. pp. 126-128 and 228-234.
Genbank Accession No. AJ003355, deposited Oct. 13, 1997.
Genbank Accession No. AA779203, deposited Feb. 6, 1998.
Genbank Accession No. U52 22, deposited Apr. 26, 1996.
Genbank Accession No. T33896, deposited Jan. 14, 1995.
Genbank Accession No. AI002979, deposited Jun. 11, 1998.
Genbank Accession No. AA806165, deposited Feb. 16, 1998.
Genbank Accession No. C06247, deposited Aug. 25, 1996.
Genbank Accession No. AA707194, deposited Jan. 5, 1998.
Genbank Accession No. AA599596, deposited Sep. 29, 1997.
Gonzalez et al. (1985) “Variation among human 28S ribosomal genes.”Proceedings of the National Academy of Sciences of USA, vol. 82:7666-7670.
Katsura et al. (1996) “Identification of the proteolytic enzyme which cleaves human p75 TNG receptor in vitro.”Biochem. And Biophys. Research Communications, vol. 222(278):298-302.
Minet et al. (1990) “Cloning and sequencing of a human cDNA coding for a multifunctional polypeptide of the purine pathway by complementation of the ade2-101 mutant inSaccharomyces cerevisiae.” Curr. Genet., vol. 18:287-291.
Oshima et al. (1998) “The human cation-independent mannose 6-phosphate receptor. Cloning and sequence of the full-length cDNA and expression of functional receptor in cos cells.”The Journal of Biological Chemistry, vol. 5:2553-2562.
Porteu et al. (1991) “Human neutrophil elastase releases a ligand-binding fragment from the 75-kDa tumor necrosis factor (TNF) receptor.”The Journal of Biological Chemistry, vol. 266:18846-18853.
Tumor Necrosis Factor Releasing Enzyme: A new family of therapeutic agents for treating arthritis and other inflammatory conditions. Corporate presentation, Meyer Pharmaceuticals. Ver 2.1, Aug. 2002.
(2000) “ENBREL(R) (etanercept) U.S. and European Long-Term Clinical Trial Data Presented at the Annual Meeting of the European League Against Rheumatism.”Company News On-Callhttp://www.prnewswire.com/cgi-bin/stories.pl?ACCT=105&STORY=/www/story/6-23-2000/ /0001250565 (Jun. 23, 2000).
(2000) “Immunex Reports Second Quarter 2000 Results.”Immunex Investor Relationshttp://www.immunex.com/investor/pressreleases/pr000719.html (Jul. 19, 2000).
Abraham et al., “p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock”,.(1997) JAMA 277:1531-1538.
Aderka et al., “Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients” (1991) Cancer Res. 51:5602-5607.
Aderka et al., “Variation in serum levels of the soluble INF receptors among healthy individuals.” (1992)Lymphokine Cytokine Res.11:157-159.
Alderson et al., “Regulation of human monocyte cell-surface and soluble CD23 (FCεRII) by granulocyte-macrophage colony-stimulating factor and IL-33” (1992)J. Immunol., 149:1252-1257.
Arbor et al., “Effects of tumour necrosis factorα (cachectin) on glucose metabolism in the rat” (1992)Mol. Cell. Biochem..112:53-59.
Argiles et al. (1988) “The metabolic environment of cancer.”Mol. Cell. Biochem.,vol. 81:3-17.
Argiles et al., “Journey from cachexia to obesity by TNF” (1997)FASEB.J., 11:743-751.
Armitage (1994) Tumor necrosis factor receptor superfamily members and their ligands. (1994) Curr. Opin. Immunul. 6:407-413.
Arner (1996) “Obesity and Insulin Resistance in Swedish Subjects”Diabetes Metabl.,vol. 13:S85-S86.
Ashkenazi et al. (1991) “Protection against endotoxic chock by a tumor necrosis factor receptor immunoadhesin.”Proc. Natl. Acad. Sci. USA, vol. 88:10535-10539.
Banner et al. (1993) “Crystal structure of the soluble human 55 kd receptor-human TNFβ complex: Implications for TNF receptor activation.”Cell, vol. 73:431-445.
Baran et al. (1988) “Characterization of the soluble murine IL-2R and estimation of its affinity for IL-2.”J. Immunol, vol. 141:539-546.
Bauditz et al. (1997) “Treatment with tumour necrosis factor inhibitor oxpetifylline does not improve corticosteroid dependent chronic active Crohn's disesase.”Gut, vol. 40:470-474.
Baum et al (1994) “Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1 regulated protein gp34.”EMBO J.,vol. 13:3992-4001.
Beretz et al. (1990) “Modulation by cytokines of leukocyte-endothelial cell interactions, implications for thrombosis.”Biorheology, vol. 27:455-460.
Bermudez et al., “Effects of stress-related hormones on macrophage receptors and response to tumor necrosis factor” (1990)Lymphokine Res.9:137-145.
Beutler et al-, “Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin” (1985)Science229:869-1371.
Bianchi et al., “Increased Brown adipose tissue activity in children with malignant disease” (1989)Horm. Metab. Res., 21:640-41.
Birkedal-Hansen et al., “Matrix metalloproteinases: A review.” (1993) Crit. Rev. Oral Biol. Med., vol. 4:197-250.
Bogdan et al. (1991) “Macrophage deactivation by interleukin 10”J. Exp. Med.,vol. 174:1549-1555.
Brockhaus et al. (1990) “Identification of 2 types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies.”Proc. Natl. Acad. Sci. USA, vol. 87:3127-3131.
Buck et al. (1996) “Tumor necrosis factorα inhibits collagen α1(1) gene expression and wound healing in a murine model of cachexia.”Am. J. Pathol.,vol. 149:195-204.
Calvano et al. (1996) “Monocyte tumor necrosis factor receptor levels as a predictor of risk in human sepsis.”Arch. Surg.,vol. 131:434-437.
Carcoran et al. (1994) “Characterization of ligand binding by the human p55 tumour-necrosis-factor.”Eur. J. Biochem.,vol. 223:831-840.
Chitambar (1991) “Shedding of transferring receptor from rat reticulocytes during maturation in vitro: Soluble transferring receptor is derived from receptor shed in vesicles.”Blood, vol. 78:2444-2450.
Colotta et al. (1993) “Interleukin-1 type II receptor: A decoy target of IL-1 that is regulated by IL-4.”Science, vol. 261:472-475.
Cornelius et al “Regulation of lipoprotein lipase mRNA content in 3T3-L1 cells by tumour necrosis factor” (1998)Biochem. J.249:765-769.
Cosman, “A family of ligands for the TNF receptor superfamily” (1994)Stem cells(Dayt.) 12:440-455.
Costelli et al., “Tumor necrosis factor-α mediates changes in tissue protein turnover in a rat cancer cachexia model” (1993)J. Clin. Invest.92:2783-2789.
Crowe et al., “A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T-lymphocytes” (1995)J. Exp. Med., 181:1205-1210.
de Waal Malefyt et al., “Interleukin 10(1L-10) inhibi
Gatanaga Tetsuya
Granger Gale A.
Bozicevic Field & Francis LLP
Brumback Brenda
Francis Carol L.
Murphy Joseph F.
LandOfFree
Treating arthritis with TNF receptor releasing enzyme does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treating arthritis with TNF receptor releasing enzyme, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating arthritis with TNF receptor releasing enzyme will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3441790